Login / Signup

Cyclooxygenase inhibitor use is associated with increased COVID-19 severity.

Justin T ReeseBen ColemanLauren E ChanHannah BlauTiffany J CallahanLuca CappellettiTommaso FontanaKatie Rebecca BradwellNomi L HarrisElena CasiraghiGiorgio ValentiniGuy KarlebachRachel R DeerJulie A McMurryMelissa A HaendelChristopher G ChuteEmily Rose PfaffRichard A MoffittHeidi M SprattJasvinder A SinghChristopher John MungallAndrew E WilliamsPeter Nick Robinson
Published in: medRxiv : the preprint server for health sciences (2021)
The association between use of COX inhibitors and COVID-19 severity was consistent across five COX inhibitors and multiple indication subcohorts. Our results align with earlier reports associating NSAID use with complications in RTI patients. Further research is needed to characterize the precise risk of individual COX inhibitors in COVID-19 patients.
Keyphrases
  • sars cov
  • coronavirus disease
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • risk factors
  • nitric oxide
  • patient reported outcomes
  • drug induced